SYNTHESIS OF UP TO TEN SAMPLE COMPOUNDS PER YEAR (Option Yr 1)

每年合成最多十种样品化合物（选项第 1 年）

• 批准号: 10701635
• 负责人: JAMES TALTON
• 金额: $ 63.73万
• 依托单位: ALCHEM LABORATORIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2023-09-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10701635
• 关键词: Contractor; Developmental Therapeutics Program; Drug Utilization; Human; Indoles; Pharmaceutical Preparations; Sampling; Therapeutic Agents; cancer therapy; clinical development; drug synthesis

The Developmental Therapeutics Program/DCTD utilizes the Drug Acquisition Initiative (DAI) to independently acquire gram quantities of all known therapeutic agents that are under human clinical development for the treatment of cancer. As part of the DAI the Drug Synthesis and Chemistry Branch periodically engages its contractors to synthesize gram quantities of select compounds. The Synthesis Target 1 Project is directed at the synthesis of a minimum of 5 grams of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, designated as CB-5339 and NSC831868.

开发治疗计划/DCTD利用药物获取计划（DAI）独立获取克量的所有已知治疗药物，这些药物正在人类临床开发中用于治疗癌症。 作为DAI的一部分，药物合成和化学分支定期聘请其承包商合成克量的选定化合物。 合成目标1项目旨在合成至少5 g 1-（4-（苄基氨基）-5，6，7，8-四氢吡啶并[2，3-d]嘧啶-2-基）-2-甲基-1H-吲哚-4-甲酰胺，命名为CB-5339和NSC 831868。